The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
about
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerZanthoxylum alkylamides ameliorate protein metabolism disorder in STZ-induced diabetic rats.VAV3 mediates resistance to breast cancer endocrine therapy.Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survivalRole of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer.EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinomaRevealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatineIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancerAnalysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.4E-BP1, a multifactor regulated multifunctional proteinInsights into the role and regulation of TCTP in skeletal muscle.Locus Mapping, Molecular Cloning, and Expression Analysis of rps6kb2, a Novel Metamorphosis-Related Gene in Chinese Tongue Sole (Cynoglossus semilaevis).Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.The Dawning of Translational Breast Cancer: From Bench to Bedside.Beyond molecular tumor heterogeneity: protein synthesis takes control.Could S6K1 immunopositivity be used to distinguish early and advanced stages of endometrioid endometrial adenocarcinoma?Could S6K1 immunopositivity be used to distinguish early and advanced stages of endometrioid endometrial adenocarcinoma?Glutamate alleviates intestinal injury, maintains mTOR and suppresses TLR4 and NOD signaling pathways in weanling pigs challenged with lipopolysaccharide
P2860
Q33414349-F8945C61-E8ED-409B-A891-88F802D6E302Q33654613-AAF18484-46A9-40E5-AC81-41DF9BABB09EQ33827037-64C073D8-BC83-422F-BB8A-79FFF65E23FCQ34240707-9C72259F-DC70-40B7-AA43-B84C9FC220EEQ34998410-1034420E-C0D9-4AAC-894E-66905D921537Q35058443-BC2EFA56-5AB2-4E9D-8FAC-9862D3652649Q35876634-7556B276-1F6F-4AFB-B55C-0DE33F1CCE94Q36095183-7B0B8C66-99CA-4C09-972B-2426F18ED6BFQ36346026-B53413ED-DFCF-4CCD-B07D-3A7533898732Q36414386-4BAE8A6E-D04B-4F67-BB15-E18830CFC5E2Q36804506-8ABFE5F8-AFD9-47B8-A4B2-878FE4FF0544Q36838384-B37AE415-9F83-48FB-BF44-6E1A7CA9E065Q37745825-942441ED-96EE-490B-AF57-2DB07A943808Q38639597-2943EC89-9DFD-4475-95F1-591CFE9A2FB5Q38717560-1C375D49-CD2D-48D0-B1F0-7ECF57D68B89Q38859693-D97DCD76-C1E1-4F73-82B1-9129D9C23B85Q38955246-D38B2DAD-679A-4C84-99CD-2AAF702215F9Q41550474-D4B38E10-158A-40A9-899D-8F14837BE8BAQ49544424-4C109BC3-BE6D-454C-8A90-2371BA9D5DD2Q49789362-9DEAF45B-911A-41C9-9299-CB8D70B586B5Q51480749-BE4C71DB-89CC-4BB4-830C-17FDE768DA79Q54942423-FAF2236A-03AF-41AF-970F-6F784A590495Q57477161-598A2420-A423-4AD4-8963-FC9D82FCB133
P2860
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The mTOR effectors 4EBP1 and S ...... sed Stockholm tamoxifen trials
@en
The mTOR effectors 4EBP1 and S ...... ed Stockholm tamoxifen trials.
@nl
type
label
The mTOR effectors 4EBP1 and S ...... sed Stockholm tamoxifen trials
@en
The mTOR effectors 4EBP1 and S ...... ed Stockholm tamoxifen trials.
@nl
prefLabel
The mTOR effectors 4EBP1 and S ...... sed Stockholm tamoxifen trials
@en
The mTOR effectors 4EBP1 and S ...... ed Stockholm tamoxifen trials.
@nl
P2093
P2860
P356
P1476
The mTOR effectors 4EBP1 and S ...... sed Stockholm tamoxifen trials
@en
P2093
Anna-Lotta Hallbeck
Bo Nordenskjöld
Dennis C Sgroi
Elin Karlsson
Gizeh Pérez-Tenorio
Josefine Bostner
Lambert Skoog
Risul Amin
Tommy Fornander
P2860
P2888
P356
10.1186/BCR3557
P577
2013-01-01T00:00:00Z
P5875
P6179
1010325951